Effect of hepatitis G virus infection on chronic hepatitis C

被引:177
作者
Tanaka, E
Alter, HJ
Nakatsuji, Y
Shih, JWK
Kim, JP
Matsumoto, A
Kobayashi, M
Kiyosawa, K
机构
[1] NIH, DEPT TRANSFUS MED, BETHESDA, MD 20852 USA
[2] SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, MATSUMOTO, NAGANO 390, JAPAN
[3] GENELABS TECHNOL INC, REDWOOD CITY, CA 94063 USA
关键词
D O I
10.7326/0003-4819-125-9-199611010-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To clarify the effect of hepatitis G virus (HGV) infection on chronic hepatitis C. Design: Retrospective study. Setting: University hospital in Matsumoto, Japan. Patients: 189 randomly selected patients with histologically proven chronic hepatitis C, including 101 patients receiving interferon-alpha. Measurements: Serum levels of HGV RNA were measured by reverse-transcription polymerase chain reaction. Clinical features, including liver histologic findings, hepatitis C virus (HCV) markers, and response of HCV to interferon-alpha were compared between HGV RNA-positive and HGV RNA-negative patients. Results: 21 of 189 (11%) patients with chronic hepatitis C were positive for HCV RNA. On average, patients with HGV RNA were younger than those without HCV RNA (mean age +/- SD, 46.6 +/- 13.0 years and 51.7 +/- 10.7 years, respectively); other demographic and clinical features were similar. The HCV genotype and HCV RNA level were distributed similarly between patients with and those without HCV infection. Ten of 101 patients with chronic hepatitis C who received interferon-alpha were positive for HCV RNA. The rate of sustained HCV response to intepferon-alpha: in patients with HGV infection (30%) was similar to that in patients without HGV infection (36%). The HGV RNA level decreased during therapy in all 9 patients in whom this value was measured. However, only 2 of these patients had a sustained HGV response after discontinuation of therapy. Conclusions: Patients who only had HCV infection did not differ from patients with HCV and HGV co-infection in clinical presentation, HCV RNA level, or response of HCV to interferon-alpha therapy. Thus, HCV infection had no apparent influence on the clinical or virologic course of HCV, infection. Hepatitis G virus was uniformly sensitive to interferon-alpha therapy, but only a few patients had a sustained virologic response.
引用
收藏
页码:740 / 743
页数:4
相关论文
共 18 条
[1]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[2]   EVALUATION OF BRANCHED DNA SIGNAL AMPLIFICATION FOR THE DETECTION OF HEPATITIS-C VIRUS-RNA [J].
ALTER, HJ ;
SANCHEZPESCADOR, R ;
URDEA, MS ;
WILBER, JC ;
LAGIER, RJ ;
DIBISCEGLIE, AM ;
SHIH, JW ;
NEUWALD, PD .
JOURNAL OF VIRAL HEPATITIS, 1995, 2 (03) :121-132
[3]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[4]   THE SIGNIFICANCE OF ANTIBODY TO HEPATITIS-C VIRUS IN PATIENTS WITH CHRONIC HEPATITIS-B [J].
FONG, TL ;
DIBISCEGLIE, AM ;
WAGGONER, JG ;
BANKS, SM ;
HOOFNAGLE, JH .
HEPATOLOGY, 1991, 14 (01) :64-67
[5]  
Jeffers L. J., 1995, Hepatology, V22, p182A, DOI 10.1016/0270-9139(95)94452-4
[6]   HEPATITIS-B AND HEPATITIS-C VIRUSES AND THEIR INTERACTION IN THE ORIGIN OF HEPATOCELLULAR-CARCINOMA [J].
KAKLAMANI, E ;
TRICHOPOULOS, D ;
TZONOU, A ;
ZAVITSANOS, X ;
KOUMANTAKI, Y ;
HATZAKIS, A ;
HSIEH, CC ;
HATZIYANNIS, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (15) :1974-1976
[7]   AN ASSAY FOR CIRCULATING ANTIBODIES TO A MAJOR ETIOLOGIC VIRUS OF HUMAN NON-A, NON-B-HEPATITIS [J].
KUO, G ;
CHOO, QL ;
ALTER, HJ ;
GITNICK, GL ;
REDEKER, AG ;
PURCELL, RH ;
MIYAMURA, T ;
DIENSTAG, JL ;
ALTER, MJ ;
STEVENS, CE ;
TEGTMEIER, GE ;
BONINO, F ;
COLOMBO, M ;
LEE, WS ;
KUO, C ;
BERGER, K ;
SHUSTER, JR ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :362-364
[8]   SIGNIFICANCE OF SERUM HEPATITIS-C VIRUS-RNA LEVELS IN CHRONIC HEPATITIS-C [J].
LAU, JYN ;
DAVIS, GL ;
KNIFFEN, J ;
QIAN, KP ;
URDEA, MS ;
CHAN, CS ;
MIZOKAMI, M ;
NEUWALD, PD ;
WILBER, JC .
LANCET, 1993, 341 (8859) :1501-1504
[9]   VIRAL AND HOST FACTORS THAT CONTRIBUTE TO EFFICACY OF INTERFERON-ALPHA(2A) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C [J].
MATSUMOTO, A ;
TANAKA, E ;
SUZUKI, T ;
OGATA, H ;
KIYOSAWA, K .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (06) :1273-1280
[10]  
NAKATSUJI Y, IN PRESS J VIRAL HEP